Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Posivie Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs FS 102 (Primary)
- Indications Adenocarcinoma; Breast cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; F-star Alpha
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
- 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 13 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.